–The Study Met Primary and All Secondary Efficacy Endpoints–
- Statistically Significant 35% Placebo-Adjusted Reduction from Baseline in Pulmonary Vascular Resistance for the Primary Endpoint (p
Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension
Watch Insmed's latest callInsmed (NASDAQ:INSM) Q3 2026 Earnings Call · Replay · Oct 29Read the transcript of Insmed (NASDAQ:INSM) Q3 2026 Earnings CallIn the deck
Story so far
- New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
- Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis
- New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results
Earlier from Insmed
- Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference
- Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study
- Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update
- Insmed To Present at the BofA Securities 2025 Health Care Conference
- Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028
Later from Insmed
- Insmed Announces Pricing of $750 Million Public Offering of Common Stock
- Insmed Announces Proposed $650 Million Public Offering of Common Stock
- Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025
- Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update
- FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
Follow Insmed into a list and get an email when it puts out news.
Follow Insmed